Asahi Kasei Corporation

3407 · TSE

Public Market Listing

3407TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Asahi Kasei Corporation are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
Glucocorticoid receptorSmall molecule
IgA Nephropathy
Phase 2
NOX1/4Small molecule
Cholestatic Liver Disease
Primary Biliary Cholangitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 July 2024Topline resultGKT137831Phase 2b TRANSFORM of setanaxib in PBC met its primary endpoint (ALP reduction versus placebo)
Calliditas Therapeutics AB · Source ↗

Financial reports

No financial reports recorded.